6-(3-(1-(3-ethyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)propoxy)-3-methanesulfonyl-2-methylpyridine | 1037764-21-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-(3-(1-(3-ethyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)propoxy)-3-methanesulfonyl-2-methylpyridine
• 英文别名: 3-Ethyl-5-[4-[3-(6-methyl-5-methylsulfonylpyridin-2-yl)oxypropyl]piperidin-1-yl]-1,2,4-oxadiazole
• CAS: 1037764-21-8
• 化学式: C₁₉H₂₈N₄O₄S
• 分子量: 408.522
• InChiKey: SEQNXIMCOAJVNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  107
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• PIPERIDINE GPCR AGONISTS
  申请人：Fyfe Matthew Colin Thor

  公开号：US20100105732A1

  公开（公告）日：2010-04-29

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

  化合物(I)的公式或其药学上可接受的盐是GPCR激动剂，并且可用于治疗肥胖症和糖尿病。
• Piperidine GPCR agonists
  申请人：Prosidion Limited

  公开号：EP2377864A1

  公开（公告）日：2011-10-19

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

  式(I)化合物： 或其药学上可接受的盐类是 GPCR 激动剂，可用于治疗肥胖症和糖尿病。
• Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
  申请人：Eickelmann Peter

  公开号：US20130109703A1

  公开（公告）日：2013-05-02

  The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.